tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
14.520USD
-0.250-1.69%
Close 02/06, 16:00ETQuotes delayed by 15 min
4.56BMarket Cap
814.81P/E TTM

Amneal Pharmaceuticals Inc

14.520
-0.250-1.69%

More Details of Amneal Pharmaceuticals Inc Company

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Amneal Pharmaceuticals Inc Info

Ticker SymbolAMRX
Company nameAmneal Pharmaceuticals Inc
IPO dateNov 18, 2009
CEOPatel (Chintu)
Number of employees8100
Security typeOrdinary Share
Fiscal year-endNov 18
Address400 Crossing Boulevard, 3rd Floor
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone19089473120
Websitehttps://amneal.com/
Ticker SymbolAMRX
IPO dateNov 18, 2009
CEOPatel (Chintu)

Company Executives of Amneal Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-151332.00%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+151496.00%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+40258.00%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+40258.00%
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Andrew S. Boyer
Mr. Andrew S. Boyer
Executive Vice President, Chief Commercial Officer - Generics
Executive Vice President, Chief Commercial Officer - Generics
--
--
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-151332.00%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+151496.00%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+40258.00%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+40258.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Oral solid
180.46M
23.00%
Distribution
96.22M
12.26%
Government label
87.75M
11.19%
Auto-injector
78.94M
10.06%
Central Nervous System
77.63M
9.90%
Other
263.51M
33.59%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oral solid
180.46M
23.00%
Distribution
96.22M
12.26%
Government label
87.75M
11.19%
Auto-injector
78.94M
10.06%
Central Nervous System
77.63M
9.90%
Other
263.51M
33.59%

Shareholding Stats

Updated: Sun, Jan 11
Updated: Sun, Jan 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholder Types
Shareholders
Proportion
Individual Investor
46.38%
Investment Advisor
19.73%
Investment Advisor/Hedge Fund
12.11%
Hedge Fund
11.57%
Private Equity
3.92%
Research Firm
1.93%
Pension Fund
0.28%
Bank and Trust
0.18%
Family Office
0.03%
Other
3.87%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
448
154.72M
55.65%
+68.38K
2025Q3
455
154.66M
56.61%
+8.55M
2025Q2
432
145.89M
53.25%
+6.99M
2025Q1
416
138.78M
50.16%
-18.42M
2024Q4
398
129.01M
49.64%
-14.17M
2024Q3
380
143.02M
47.07%
+6.97M
2024Q2
372
135.82M
34.71%
+37.56M
2024Q1
356
97.40M
32.81%
-3.83M
2023Q4
348
89.35M
29.61%
+7.08M
2023Q3
338
82.03M
56.21%
+4.32M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Tushar Bhikhubhai)
48.58M
15.45%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.15%
--
--
Oct 03, 2025
Patel (Dipan)
23.83M
7.58%
--
--
Oct 03, 2025
Patel (Chirag K)
22.13M
7.04%
--
--
Aug 06, 2025
Akram (Mahesh)
20.56M
6.54%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
17.90M
5.69%
+403.58K
+2.31%
Sep 30, 2025
Rubric Capital Management LP
12.33M
3.92%
+624.61K
+5.33%
Sep 30, 2025
TPG Capital, L.P.
12.33M
3.92%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
11.34M
3.61%
+697.25K
+6.55%
Sep 30, 2025
Citadel Advisors LLC
5.73M
1.82%
+104.62K
+1.86%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
3.08%
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2%
Invesco Dorsey Wright Healthcare Momentum ETF
0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
0.83%
First Trust NASDAQ Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.72%
iShares U.S. Pharmaceuticals ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.48%
WisdomTree US SmallCap Fund
0.36%
View more
Invesco Pharmaceuticals ETF
Proportion3.08%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.83%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.78%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.72%
iShares U.S. Pharmaceuticals ETF
Proportion0.68%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
WisdomTree US SmallCap Fund
Proportion0.36%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI